Hims & Hers Health, Inc. (NYSE:HIMS) CEO Andrew Dudum Sells 188,888 Shares

Hims & Hers Health, Inc. (NYSE:HIMS) CEO Andrew Dudum sold 188,888 shares of the company’s stock in a transaction on Thursday, April 4th. The stock was sold at an average price of $14.97, for a total transaction of $2,827,653.36. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.

Andrew Dudum also recently made the following trade(s):

• On Wednesday, March 20th, Andrew Dudum sold 50,361 shares of Hims & Hers Health stock. The shares were sold at an average price of $16.34, for a total transaction of $822,898.74.
• On Tuesday, February 13th, Andrew Dudum sold 97,208 shares of Hims & Hers Health stock. The shares were sold at an average price of $9.58, for a total transaction of $931,252.64.
• On Monday, January 29th, Andrew Dudum sold 15,100 shares of Hims & Hers Health stock. The shares were sold at an average price of $9.01, for a total transaction of $136,051.00.
• On Thursday, January 25th, Andrew Dudum sold 127,688 shares of Hims & Hers Health stock. The shares were sold at an average price of $9.08, for a total transaction of $1,159,407.04.

Hims & Hers Health Stock Performance

Hims & Hers Health stock traded up $0.37 during midday trading on Monday, reaching $14.88. 3,352,460 shares of the company were exchanged, compared to its average volume of 4,715,257. The firm’s 50-day simple moving average is $12.64 and its 200-day simple moving average is $9.38. The company has a market capitalization of $3.19 billion, a price-to-earnings ratio of -133.91 and a beta of 0.91. Hims & Hers Health, Inc. has a 1 year low of $5.65 and a 1 year high of $17.16.

Hims & Hers Health (NYSE:HIMS) last announced its earnings results on Monday, February 26th. The company reported $0.01 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.02) by $0.03. Hims & Hers Health had a negative return on equity of 7.21% and a negative net margin of 2.70%. The company had revenue of $246.60 million for the quarter, compared to analyst estimates of $245.84 million. During the same period in the prior year, the company posted ($0.05) EPS. Hims & Hers Health’s quarterly revenue was up 47.4% on a year-over-year basis. On average, analysts forecast that Hims & Hers Health, Inc. will post 0.1 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in the stock. Forerunner Ventures Management LLC acquired a new position in Hims & Hers Health during the fourth quarter worth about $86,836,000. Marshall Wace LLP boosted its position in shares of Hims & Hers Health by 99.4% in the 4th quarter. Marshall Wace LLP now owns 4,487,038 shares of the company’s stock valued at $28,762,000 after purchasing an additional 2,236,609 shares during the period. Millennium Management LLC boosted its position in shares of Hims & Hers Health by 145.8% in the 4th quarter. Millennium Management LLC now owns 3,524,750 shares of the company’s stock valued at $22,594,000 after purchasing an additional 2,090,833 shares during the period. Samlyn Capital LLC acquired a new position in shares of Hims & Hers Health in the 1st quarter valued at $17,391,000. Finally, State Street Corp boosted its position in shares of Hims & Hers Health by 147.8% in the 2nd quarter. State Street Corp now owns 2,597,684 shares of the company’s stock valued at $11,768,000 after purchasing an additional 1,549,546 shares during the period. 63.52% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

A number of research analysts have commented on HIMS shares. Guggenheim upped their target price on shares of Hims & Hers Health from $15.00 to $17.00 and gave the company a “buy” rating in a research report on Tuesday, February 27th. Citigroup raised their target price on shares of Hims & Hers Health from $12.00 to $16.00 and gave the company a “buy” rating in a report on Tuesday, February 27th. Tigress Financial increased their price target on shares of Hims & Hers Health from $14.00 to $15.00 and gave the company a “buy” rating in a research note on Friday, January 5th. Leerink Partnrs reiterated a “market perform” rating on shares of Hims & Hers Health in a research note on Monday, February 26th. Finally, Truist Financial raised their target price on shares of Hims & Hers Health from $10.00 to $13.00 and gave the stock a “hold” rating in a research report on Tuesday, February 27th. Five equities research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $13.45.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers.